162 related articles for article (PubMed ID: 35702782)
1. Comparative Dynamic Features of Apo and Bound MDM2 Protein Reveal the Mechanism of Inhibitor Recognition for Anti-Cancer Activity.
I El Habbash A; El Rashedy A; Soliman MES
Curr Med Chem; 2023; 30(10):1193-1206. PubMed ID: 35702782
[TBL] [Abstract][Full Text] [Related]
2. Probing Alterations in MDM2 Catalytic Core Structure Effect of Garcinia Mangostana Derivatives: Insight from Molecular Dynamics Simulations.
El Habbash AI; Aljoundi A; Elamin G; Soliman MES
Cell Biochem Biophys; 2022 Dec; 80(4):633-645. PubMed ID: 36184717
[TBL] [Abstract][Full Text] [Related]
3. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations.
Espinoza-Fonseca LM; Trujillo-Ferrara JG
Biopolymers; 2006 Nov; 83(4):365-73. PubMed ID: 16817233
[TBL] [Abstract][Full Text] [Related]
4. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the Free-Energy Landscape of MDM2 Protein-Ligand Interactions by Steered Molecular Dynamics Simulations.
Hu G; Xu S; Wang J
Chem Biol Drug Des; 2015 Dec; 86(6):1351-9. PubMed ID: 26032728
[TBL] [Abstract][Full Text] [Related]
6. Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics.
Verkhivker GM
PLoS One; 2012; 7(7):e40897. PubMed ID: 22815859
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
9. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
10. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
[TBL] [Abstract][Full Text] [Related]
11. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
12. Binding induced folding in p53-MDM2 complex.
Chen HF; Luo R
J Am Chem Soc; 2007 Mar; 129(10):2930-7. PubMed ID: 17302414
[TBL] [Abstract][Full Text] [Related]
13. Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: molecular dynamics simulation and free energy analysis.
Chen J; Wang J; Xu B; Zhu W; Li G
J Mol Graph Model; 2011 Sep; 30():46-53. PubMed ID: 21764342
[TBL] [Abstract][Full Text] [Related]
14. A computational analysis of binding modes and conformation changes of MDM2 induced by p53 and inhibitor bindings.
Chen J; Wang J; Zhu W; Li G
J Comput Aided Mol Des; 2013 Nov; 27(11):965-74. PubMed ID: 24264557
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study.
Lee HJ; Srinivasan D; Coomber D; Lane DP; Verma CS
Cell Cycle; 2007 Nov; 6(21):2604-11. PubMed ID: 17957142
[TBL] [Abstract][Full Text] [Related]
16. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
Niu RJ; Zheng QC; Zhang JL; Zhang HX
J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
[TBL] [Abstract][Full Text] [Related]
18. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
[TBL] [Abstract][Full Text] [Related]
19. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
[TBL] [Abstract][Full Text] [Related]
20. α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.
Sang P; Shi Y; Lu J; Chen L; Yang L; Borcherds W; Abdulkadir S; Li Q; Daughdrill G; Chen J; Cai J
J Med Chem; 2020 Feb; 63(3):975-986. PubMed ID: 31971801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]